News & Events
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45. 95 per share. All of the shares to be sold in the offering are to be sold by Crinetics.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced that it intends to offer and sell, subject to market and other conditions, $350 million of shares of its common stock in a proposed underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional $52. 5 million of shares of common stock.
READ MORECrinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
Strong PALSONIFY U. S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December.
READ MORECrinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Crinetics announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a. m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.
READ MORECrinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO - December 18, 2025 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph. D.
READ MORECrinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics announced that Scott Struthers, Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J. P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 AM Pacific Time.
READ MORECrinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a novel, once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital CAH. The phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAH.
READ MORECrinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock unit (“RSU”) awards to 9 new non-executive employees.
READ MORECrinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Crinetics announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing solid tumors. Initiation of the trial marks a milestone for Crinetics’ novel nonpeptide drug conjugate platform.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
